• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疫苗介导的埃博拉病毒跨物种抗体诱导与糖蛋白七肽重复 2/膜近端外连接上保守表位结合。

Vaccine-Mediated Induction of an Ebolavirus Cross-Species Antibody Binding to Conserved Epitopes on the Glycoprotein Heptad Repeat 2/Membrane-Proximal External Junction.

机构信息

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Maryland.

出版信息

J Infect Dis. 2018 Nov 22;218(suppl_5):S537-S544. doi: 10.1093/infdis/jiy450.

DOI:10.1093/infdis/jiy450
PMID:30137549
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6249595/
Abstract

The membrane-proximal external regions (MPER) of the human immunodeficiency virus envelope glycoprotein (GP) generate broadly reactive antibody responses and are the focus of vaccine development efforts. The conservation of amino acids within filovirus GP heptad repeat region (HR)2/MPER suggests that it may also represent a target for a pan-filovirus vaccine. We immunized a cynomolgus macaque against Ebola virus (EBOV) using a deoxyribonucleic acid/adenovirus 5 prime/boost strategy, sequenced memory B-cell receptors, and tested the antibodies for functional activity against EBOV GP. Antibody ma-C10 bound to GP with an affinity of 48 nM and was capable of inducing antibody-dependent cellular cytotoxicity. Three-dimensional reconstruction of single-particle, negative-stained, electron microscopy showed that ma-C10 bound to the HR2/MPER, and enzyme-linked immunosorbent assay reveals it binds to residues 621-631. More importantly, ma-C10 was found to bind to the GP of the 3 most clinically relevant Ebolavirus species, suggesting that a cross-species immunogen strategy targeting the residues in this region may be a feasible approach for producing a pan-filovirus vaccine.

摘要

人类免疫缺陷病毒包膜糖蛋白(GP)的膜近端外部区域(MPER)产生广泛反应性的抗体应答,是疫苗开发工作的重点。丝状病毒 GP 七肽重复区(HR)2/MPER 内氨基酸的保守性表明,它也可能是泛丝状病毒疫苗的一个靶标。我们使用 DNA/腺病毒 5 型的核酸/腺病毒 5 型的启动/增强策略,对食蟹猴进行埃博拉病毒(EBOV)免疫接种,对记忆 B 细胞受体进行测序,并测试了针对 EBOV GP 的抗体的功能活性。抗体 ma-C10 与 GP 的亲和力为 48 nM,能够诱导抗体依赖性细胞毒性。单颗粒、负染、电子显微镜的三维重建显示,ma-C10 与 HR2/MPER 结合,酶联免疫吸附试验显示其与残基 621-631 结合。更重要的是,发现 ma-C10 与 3 种最具临床相关性的埃博拉病毒种的 GP 结合,这表明针对该区域残基的跨物种免疫原策略可能是产生泛丝状病毒疫苗的可行方法。

相似文献

1
Vaccine-Mediated Induction of an Ebolavirus Cross-Species Antibody Binding to Conserved Epitopes on the Glycoprotein Heptad Repeat 2/Membrane-Proximal External Junction.疫苗介导的埃博拉病毒跨物种抗体诱导与糖蛋白七肽重复 2/膜近端外连接上保守表位结合。
J Infect Dis. 2018 Nov 22;218(suppl_5):S537-S544. doi: 10.1093/infdis/jiy450.
2
Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.靶向丝状病毒糖蛋白内新型保守表位的猕猴单克隆抗体。
J Virol. 2015 Oct 14;90(1):279-91. doi: 10.1128/JVI.02172-15. Print 2016 Jan 1.
3
Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.来自人类幸存者的广谱中和抗体靶向埃博拉病毒糖蛋白 HR2-MPER 区域中的保守位点。
Nat Microbiol. 2018 Jun;3(6):670-677. doi: 10.1038/s41564-018-0157-z. Epub 2018 May 7.
4
Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.三价副流感病毒载体埃博拉病毒疫苗诱导的抗体介导的保护机制。
J Virol. 2019 Feb 5;93(4). doi: 10.1128/JVI.01845-18. Print 2019 Feb 15.
5
Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region.基于埃博拉病毒糖蛋白 HR2-MPER 区域的表位聚焦免疫原设计。
PLoS Pathog. 2022 May 18;18(5):e1010518. doi: 10.1371/journal.ppat.1010518. eCollection 2022 May.
6
A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.一种异源初免-加强型埃博拉病毒疫苗方案可诱导持久的中和抗体应答,并防止小鼠感染埃博拉病毒样颗粒。
Antiviral Res. 2017 Sep;145:54-59. doi: 10.1016/j.antiviral.2017.07.009. Epub 2017 Jul 18.
7
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.抗体对于 rVSV/ZEBOV-GP 介导的非人类灵长类动物抵抗致死性埃博拉病毒攻击的保护是必要的。
Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893-8. doi: 10.1073/pnas.1209591110. Epub 2013 Jan 14.
8
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.展示针对新兴致病性埃博拉病毒物种的交叉保护疫苗免疫。
PLoS Pathog. 2010 May 20;6(5):e1000904. doi: 10.1371/journal.ppat.1000904.
9
Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.重组改良安卡拉痘苗病毒产生埃博拉病毒样颗粒。
J Virol. 2017 May 12;91(11). doi: 10.1128/JVI.00343-17. Print 2017 Jun 1.
10
Epitope mapping of Ebola virus dominant and subdominant glycoprotein epitopes facilitates construction of an epitope-based DNA vaccine able to focus the antibody response in mice.埃博拉病毒主要和次要糖蛋白表位的抗原表位作图有助于构建一种基于表位的 DNA 疫苗,该疫苗能够使小鼠的抗体反应集中。
Hum Vaccin Immunother. 2017 Dec 2;13(12):2883-2893. doi: 10.1080/21645515.2017.1347740. Epub 2017 Jul 12.

引用本文的文献

1
Inducing broad-based immunity against viruses with pandemic potential.诱导针对具有大流行潜力病毒的广泛免疫。
Immunity. 2022 May 10;55(5):738-748. doi: 10.1016/j.immuni.2022.04.010.

本文引用的文献

1
Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody.表面基质筛选鉴定出能提高近泛 HIV-1 中和抗体效力的半特异性相互作用。
Cell Rep. 2018 Feb 13;22(7):1798-1809. doi: 10.1016/j.celrep.2018.01.023.
2
Intramuscular Adeno-Associated Virus-Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice.肌内注射腺相关病毒介导的单克隆抗体表达可提供针对埃博拉病毒感染的 100%保护作用。
J Infect Dis. 2018 Mar 5;217(6):916-925. doi: 10.1093/infdis/jix644.
3
Structure of the Ebola virus envelope protein MPER/TM domain and its interaction with the fusion loop explains their fusion activity.埃博拉病毒包膜蛋白 MPER/TM 结构域及其与融合环的相互作用解释了它们的融合活性。
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):E7987-E7996. doi: 10.1073/pnas.1708052114. Epub 2017 Sep 5.
4
Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.基于恩夫韦肽(T20)的脂肽是一种有效的HIV-1细胞融合抑制剂:对病毒进入和抑制的意义。
J Virol. 2017 Aug 24;91(18). doi: 10.1128/JVI.00831-17. Print 2017 Sep 15.
5
Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.一名人类幸存者的抗体确定了针对埃博拉病毒广泛保护的易损位点。
Cell. 2017 May 18;169(5):878-890.e15. doi: 10.1016/j.cell.2017.04.037.
6
Toremifene interacts with and destabilizes the Ebola virus glycoprotein.托瑞米芬与埃博拉病毒糖蛋白相互作用并使其不稳定。
Nature. 2016 Jul 7;535(7610):169-172. doi: 10.1038/nature18615. Epub 2016 Jun 29.
7
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.强效中和抗体对致死性埃博拉病毒感染的保护性单药治疗。
Science. 2016 Mar 18;351(6279):1339-42. doi: 10.1126/science.aad5224. Epub 2016 Feb 25.
8
Structural and molecular basis for Ebola virus neutralization by protective human antibodies.保护性人类抗体中和埃博拉病毒的结构和分子基础。
Science. 2016 Mar 18;351(6279):1343-6. doi: 10.1126/science.aad6117. Epub 2016 Feb 25.
9
Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.从2014年埃博拉病毒疫情的一名幸存者体内分离出强效中和抗体。
Science. 2016 Mar 4;351(6277):1078-83. doi: 10.1126/science.aad5788. Epub 2016 Feb 18.
10
Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.自然感染埃博拉病毒的人类幸存者体内的交叉反应性和强效中和抗体反应
Cell. 2016 Jan 28;164(3):392-405. doi: 10.1016/j.cell.2015.12.022. Epub 2016 Jan 21.